Short-term Efficacy and Safety of Omidenepag Isopropyl 0.002% w/v Therapy for Patients with Primary Open-angle Glaucoma and Ocular Hypertension

IF 0.1 Q4 OPHTHALMOLOGY
Jung Soo Kim, Jung Lim Kim
{"title":"Short-term Efficacy and Safety of Omidenepag Isopropyl 0.002% w/v Therapy for Patients with Primary Open-angle Glaucoma and Ocular Hypertension","authors":"Jung Soo Kim, Jung Lim Kim","doi":"10.3341/jkos.2023.64.9.819","DOIUrl":null,"url":null,"abstract":"Purpose: To analyze the short-term efficacy and safety of omidenepag isopropyl 0.002% (w/v) in patients with primary open-angle glaucoma and ocular hypertension.Methods: Data on 36 patients with primary open-angle glaucoma and ocular hypertension treated with omidenepag isopropyl 0.002% (w/v) from January 2021 to May 2022 were retrospectively analyzed. We investigated whether the drug lowered the intraocular pressure (IOP) at 1 and 3 months compared to baseline. Possible side effects were sought at each visit.Results: The mean patient age was 59.2 years at the time of treatment. Of the 36 patients, 33 had primary open-angle glaucoma and 3 had ocular hypertension. The baseline IOP was 15.9 ± 3.6 mmHg, which significantly decreased to 13.7 ± 2.8 and 13.4 ± 2.9 mmHg at 1 and 3 months, respectively, following instillation of omidenepag isopropyl 0.002% (w/v) (both <i>p</i> < 0.01). Twelve patients (29.2%) experienced side effects including hyperemia, ocular pain, and itching but only two (5.5%) stopped using the medication.Conclusions: In the short-term, ominedepag isopropyl 0.002% (w/v) is effective and safe in patients with primary open-angle glaucoma and ocular hypertension.","PeriodicalId":17341,"journal":{"name":"Journal of The Korean Ophthalmological Society","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of The Korean Ophthalmological Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3341/jkos.2023.64.9.819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To analyze the short-term efficacy and safety of omidenepag isopropyl 0.002% (w/v) in patients with primary open-angle glaucoma and ocular hypertension.Methods: Data on 36 patients with primary open-angle glaucoma and ocular hypertension treated with omidenepag isopropyl 0.002% (w/v) from January 2021 to May 2022 were retrospectively analyzed. We investigated whether the drug lowered the intraocular pressure (IOP) at 1 and 3 months compared to baseline. Possible side effects were sought at each visit.Results: The mean patient age was 59.2 years at the time of treatment. Of the 36 patients, 33 had primary open-angle glaucoma and 3 had ocular hypertension. The baseline IOP was 15.9 ± 3.6 mmHg, which significantly decreased to 13.7 ± 2.8 and 13.4 ± 2.9 mmHg at 1 and 3 months, respectively, following instillation of omidenepag isopropyl 0.002% (w/v) (both p < 0.01). Twelve patients (29.2%) experienced side effects including hyperemia, ocular pain, and itching but only two (5.5%) stopped using the medication.Conclusions: In the short-term, ominedepag isopropyl 0.002% (w/v) is effective and safe in patients with primary open-angle glaucoma and ocular hypertension.
0.002%异丙基奥米尼帕格w/v治疗原发性开角型青光眼和高眼压的近期疗效和安全性
目的:分析0.002%异丙基奥米尼帕格(w/v)治疗原发性开角型青光眼合并高眼压的近期疗效和安全性。方法:回顾性分析2021年1月至2022年5月用0.002%异丙基奥米尼帕治疗的36例原发性开角型青光眼伴高眼压患者的资料。我们调查了与基线相比,该药是否降低了1个月和3个月的眼压(IOP)。每次就诊时都要寻找可能的副作用。结果:患者治疗时平均年龄为59.2岁。36例患者中33例为原发性开角型青光眼,3例为高眼压。基线IOP为15.9±3.6 mmHg,在滴注0.002%异丙基(w/v) omidenepag后1个月和3个月分别显著降至13.7±2.8和13.4±2.9 mmHg(均为<i>p</i>& lt;0.01)。12名患者(29.2%)出现充血、眼痛和瘙痒等副作用,但只有2名患者(5.5%)停止使用该药。结论:0.002%奥米地帕格异丙基(w/v)在短期内对原发性开角型青光眼合并高眼压患者是安全有效的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
126
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信